Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Orion Office REIT Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Orion Office REIT Inc trades at $2.78 (market cap $158.01M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 187.3× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.89% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ONL | |
|---|---|---|
Market Cap | $29.60B | $158.01M |
Sector | Health | Real Estate |
52-Week High | $491.22 | $3.04 |
52-Week Low | $205.48 | $1.93 |
Enterprise Value | $27.56B | $574.95M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
ONL trades at $2.83, up 2.91% with a bullish technical signal and strong moving average support. The company reported mixed Q2 2026 results with an EPS beat but continues to face fundamental challenges including declining revenue from $208M in 2022 to $148M in 2025 and negative net margins. Recent news highlights strategic review progress and portfolio repositioning efforts.
The outlook remains cautious despite technical strength. While the stock shows bullish momentum and pays consistent dividends, persistent revenue declines, negative profitability metrics, and high debt levels pose significant risks. Analyst sentiment is evenly split between Buy and Hold recommendations, reflecting uncertainty about the company's turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
